BRIEF-Ionis Pharmaceuticals reports positive data from phase 2 study of ionis-gcgr rx in patients with type 2 diabetes
Jan 4 Ionis Pharmaceuticals Inc :
* Ionis Pharmaceuticals reports positive data from phase 2 study of ionis-gcgr rx in patients with type 2 diabetes
* Ionis Pharmaceuticals - company to present top-line results at pipeline update webcast on January 5
* Ionis Pharmaceuticals-statistically significant improvements in hemoglobin a1c (hba1c), other measures of glucose control after 26 weeks of treatment Source text for Eikon: Further company coverage:
UPDATE 2-Ahead of NAFTA talks, U.S. sets 20 pct duties on Canadian softwood lumber
WASHINGTON, April 24 The United States will impose preliminary anti-subsidy duties averaging 20 percent on imports of Canadian softwood lumber, Commerce Secretary Wilbur Ross said on Monday, escalating a long-running trade dispute between the two neighbors.